The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted
in significant casualties and put immense strain on public health systems worldwide, leading …

Background The efficacy of simvastatin in critically ill patients with coronavirus disease 2019
(Covid-19) is unclear. Methods In an ongoing international, multifactorial, adaptive platform …

Despite the fact that coronavirus disease 2019 (COVID-19) treatment and management are
now considerably regulated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

Background Early treatment of coronavirus disease 2019 (COVID-19) with remdesivir in high-
risk patients, including those with immunosuppression of different causes, has not been …

The emergence of human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
poses significant challenges to global public health. Despite the extensive efforts of …

Acute respiratory viral infections (ARVI) are the most common illnesses worldwide. In some
instances, mild cases of ARVI progress to hyperinflammatory responses, which are …

The COVID-19 pandemic exposed crucial fault lines in society both within and between
different societies. Over the past 3 years, inequity has been highlighted in several areas …

Background Effective disease surveillance, including that for COVID-19, is compromised
without a standardised method for categorising the immunosuppressed as a clinical risk …

Fluvoxamine, a selective serotonin reuptake inhibitor with anti-inflammatory properties, has
gained attention as a repurposed drug to treat COVID-19. We aimed to explore the potential …